NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR agonists have demonstrated efficacy in ameliorating liver disease progression and attenuating fibrosis across various etiologies, as evidenced by experimental animal models of cholestatic, toxic, and NASH-induced fibrosis [206,207,208,209,210,211,212,213,214,215,216,217,218].